The Swiss pharma group Sandoz has inaugurated a US$99 million biosimilars development centre in Ljubljana, the first of its three major investment projects in Slovenia to create an end-to-end in-house biosimilar development and manufacturing hub in Europe. According to Sandoz, the fully digitally ...